Short Interest of The Day: Argos Therapeutics Incorporated (NASDAQ:ARGS) Stock Is Shorted More

November 24, 2016 - By Linda Rogers   ·   0 Comments

Short Interest of The Day: Argos Therapeutics Incorporated (NASDAQ:ARGS) Stock Is Shorted More

The stock of Argos Therapeutics Incorporated (NASDAQ:ARGS) registered an increase of 0.14% in short interest. ARGS’s total short interest was 2.22M shares in November as published by FINRA. Its up 0.14% from 2.22 million shares, reported previously. With 82,600 shares average volume, it will take short sellers 27 days to cover their ARGS’s short positions. The short interest to Argos Therapeutics Incorporated’s float is 10.37%. The stock increased 1.00% or $0.05 on November 23, hitting $5.05. About 95,330 shares traded hands. Argos Therapeutics Inc (NASDAQ:ARGS) has declined 30.34% since April 22, 2016 and is downtrending. It has underperformed by 35.75% the S&P500.

Argos Therapeutics, Inc. is an immuno-oncology company. The company has a market cap of $206.23 million. The Firm is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. It currently has negative earnings. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Insitutional Activity: The institutional sentiment decreased to 2.56 in 2016 Q2. Its down 2.27, from 4.83 in 2016Q1. The ratio fall, as 1 funds sold all Argos Therapeutics Inc shares owned while 5 reduced positions. 19 funds bought stakes while 10 increased positions. They now own 8.64 million shares or 155.45% more from 3.38 million shares in 2016Q1.
Blackrock Limited Com has 2,924 shares for 0% of their US portfolio. Nationwide Fund holds 0% of its portfolio in Argos Therapeutics Inc (NASDAQ:ARGS) for 6,632 shares. Vanguard last reported 0% of its portfolio in the stock. Tower Rech Cap Lc (Trc) holds 200 shares or 0% of its portfolio. Blackrock Fund Advisors owns 281,679 shares or 0% of their US portfolio. Royal Retail Bank Of Canada owns 800 shares or 0% of their US portfolio. State Common Retirement Fund, a New York-based fund reported 17,900 shares. The New York-based Tiaa Cref Inv Mgmt Ltd Llc has invested 0% in Argos Therapeutics Inc (NASDAQ:ARGS). Amer Gru holds 0% of its portfolio in Argos Therapeutics Inc (NASDAQ:ARGS) for 6,139 shares. Bank Of Ny Mellon holds 52,215 shares or 0% of its portfolio. Keybank Natl Association Oh has 24,358 shares for 0% of their US portfolio. Northern has 116,094 shares for 0% of their US portfolio. Blackrock holds 0% of its portfolio in Argos Therapeutics Inc (NASDAQ:ARGS) for 533 shares. The Germany-based Deutsche Retail Bank Ag has invested 0% in Argos Therapeutics Inc (NASDAQ:ARGS). Kcg Hldg, a New Jersey-based fund reported 26,554 shares.

Insider Transactions: Since August 19, 2016, the stock had 8 buys, and 0 selling transactions for $1.78 million net activity. $223,366 worth of Argos Therapeutics Inc (NASDAQ:ARGS) shares were bought by Pharmstandard International S.A..

Argos Therapeutics Inc (NASDAQ:ARGS) Ratings Coverage

Out of 4 analysts covering Argos Therapeutics (NASDAQ:ARGS), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Argos Therapeutics has been the topic of 5 analyst reports since November 16, 2015 according to StockzIntelligence Inc. Needham maintained the stock with “Buy” rating in Tuesday, November 17 report. The company was maintained on Thursday, August 11 by FBR Capital. Roth Capital maintained the shares of ARGS in a report on Tuesday, April 19 with “Buy” rating. On Monday, November 16 the stock rating was maintained by FBR Capital with “Outperform”. The stock has “Market Outperform” rating given by JMP Securities on Wednesday, March 9.

ARGS Company Profile

Argos Therapeutics, Inc. (Argos), incorporated on May 8, 1997, is an immuno-oncology company. The Firm is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s product candidates include AGS-003 and AGS-004.

More important recent Argos Therapeutics Inc (NASDAQ:ARGS) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on March 04, 2012, also Reuters.com published article titled: “BRIEF-Russia’s Pharmstandard invests in Argos Therapeutics Inc”, Globenewswire.com published: “Argos Therapeutics Announces Pricing of $50 Million Public Offering of Common …” on July 28, 2016. More interesting news about Argos Therapeutics Inc (NASDAQ:ARGS) was released by: Streetinsider.com and their article: “Argos Therapeutics (ARGS), Cellthera Pharm Present AGS-003 Mouse Model Data” with publication date: November 18, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Linda Rogers

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>